ICARE-TNBC : Immune checkpoint-associated cardiotoxicity risk evaluation in early-stage triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects younger women. Pembrolizumab combined with chemotherapy improves outcomes in TNBC. However, anthracyclines, pembrolizumab and radiotherapy are potentially cardiotoxic but cardiovascular safety data in routine prac...